The article continued on the next page:

So, apabetalone, if successful, can claim a large section of the unmet medical need. Further, another unmanaged risk of inflammation which is usually caused only by an epigenetic modification has a specific BET-inhibitor potential. However, due to initial lack of clarity they had to restate their endpoints at an advanced stage of Phase 2 trials. A repetition of such a scenario might have been a major setback at such an advanced trial stage.

Thus FDA acceptance of the analysis plan and the endpoint of the trial comes as a relief on the projected timeline of the candidate. As apabetalone is a twice daily tablet, it has the potential to become an affordable and easy to administer therapy for all patients. It has consistently proved its safety parameters in all previous trial phases.

The company is a microcap with a $247.905M market cap and is trading toward the higher end of its 52-week range at $1.39. The financial potential of the company’s lead is not yet fully realized and may be delayed until its full approval and commercialization. Moreover, RVXCF is an extremely thinly traded OTC stock from Canada. General caution regarding OTC stocks involve problems of liquidity and volatility risk. RVXCF also shows a high beta of 3.37. Nevertheless, the promising candidate with its game-changing potential makes the company an attention grabber.